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Dengue is a mosquito-borne flavivirus that is spreading at an
unprecedented rate and has developed into a major health and
economic burden in over 50 countries. Even though infected
individuals develop potent and long-lasting serotype-specific neu-
tralizing antibodies (Abs), the epitopes engaged by human neu-
tralizing Abs have not been identified. Here, we demonstrate that
the dengue virus (DENV)-specific serum Ab response in humans
consists of a large fraction of cross-reactive, poorly neutralizing Abs
and a small fraction of serotype-specific, potently inhibitory Abs.
Although many mouse-generated, strongly neutralizing monoclo-
nal antibodies (mAbs) recognize epitopes that are present on
recombinant DENV envelope (E) proteins, unexpectedly, the ma-
jority of neutralizing Abs in human immune sera bound to intact
virions but not to the ectodomain of purified soluble E proteins.
These conclusions with polyclonal Abs were confirmed with newly
generated human mAbs derived from DENV-immune individuals.
Two of three strongly neutralizing humanmAbs bound to E protein
epitopes that were preserved on the virion but not on recombinant
E (rE) protein. We propose that humans produce Abs that neutralize
DENV infection by binding a complex, quaternary structure epitope
that is expressed only when E proteins are assembled on a virus
particle. Mapping studies indicate that this epitope has a footprint
that spans adjacent E protein dimers and includes residues at the
hinge between domains I and II of E protein. These results have
significant implications for the DENV Ab and vaccine field.
Dengue viruses (DENVs) are emerging arboviruses and thecausative agents of dengue fever and dengue hemorrhagic
fever (DHF). The DENV complex consists of four distinct but
related viruses, designated as serotypes (1, 2). A person infected
with DENV develops an antibody (Ab) response that, to varying
degrees, cross-reacts with all four serotypes. Despite the cross-
reactivity, Abs that are produced durably only prevent reinfection
by the same homologous serotype. Serotype-specific neutralizing
Abs can be detected 60 y after a primary infection, suggesting that
Abs provide lifelong protection against the homologous serotype
(3). People experiencing a secondary DENV infection with a
different (heterologous) serotype face a greater risk for devel-
oping DHF. Ab-dependent enhancement by cross-reactive, weakly
neutralizing Abs is themost widely suggested theory explaining the
higher risk for DHF associated with secondary infection (4). The
identity of DENV epitopes recognized by human Abs responsible
for potent and long-term neutralization remains unknown. This is
a significant knowledge gap impeding the current global effort to
develop dengue vaccines that induce protective neutralizing Abs
and not cross-reactive Abs with potential to enhance disease.
The DENV envelope contains two integral membrane proteins
designated envelope (E) and premembrane/membrane (prM/M)
proteins. DENV E protein, which binds to cellular receptors
and mediates viral fusion during entry, is thought to be the major
target of neutralizing Abs (5). The ectodomain of E proteins has
been crystallized, and atomic structures have been determined for
several flaviviruses (6–9). Individual subunits of E protein consist of
three β-barrel domains designated domains I (EDI), II (EDII), and
III (EDIII), with the native protein forming a head-to-tail homo-
dimer on the mature virion. The mature DENV particle consists of
90 dimers that cover the surface of the virion (10). Although several
groups have characterized mouse monoclonal antibodies (mAbs)
that neutralize DENV infection (4, 5) and mapped them to all
three domains on the E protein (5, 11, 12), the strongest neutral-
izing mouse mAbs were serotype-specific and bound to two over-
lapping and adjacent epitopes on the lateral ridge and A-strand of
EDIII (11–16).
To understand how human Abs neutralize DENV, investi-
gators have begun to characterize human immune sera and hu-
man monoclonal Abs (hmAbs) (17–19). Humans also produce
EDIII-reactive Abs, including strongly neutralizing mAbs that
bind to similar epitopes recognized by murine EDIII Abs (18, 20).
However, several recent observations indicate that EDIII-specific
Abs alone are unlikely to account for the strong type-specific
neutralizing Ab responses observed in people following natural
infections. DENV-immune humans have low levels of serum
EDIII-specific Abs, and these sera retained potently neutralizing
activity even after depletion of EDIII-binding Abs (21–23).
Moreover, recombinant DENVs with mutations in EDIII epito-
pes recognized by neutralizing Abs remained sensitive to neu-
tralization by human DENV-immune sera (24). Collectively,
these observations suggest that humans produce neutralizing Abs
that bind to epitopes other than those on EDIII. Here, we char-
acterized polyclonal sera and hmAbs generated from DENV-
immune individuals to identify DENV epitopes engaged by
potently neutralizing human Abs. We demonstrate that human
neutralizing Abs recognize a complex epitope that is preserved on
the intact virion but is not present on the soluble E protein.
Results
Depletion of Homologous DENV-Specific Abs from Immune Sera.
Studies were undertaken to characterize Abs in human immune
sera responsible for potent and long-term neutralization of
the homologous virus serotype. We assembled a panel of eight
immune sera from healthy volunteers who had been exposed to
primary DENV2 or DENV3 infections ∼2–9 y before blood
collection (Table S1). Human serum from individuals lacking a
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past history of DENV infections (confirmed by ELISA and
neutralization assays) was used as a negative control.
To define the Ab subpopulation in immune sera responsible
for DENV neutralization, we developed a bead-based technique
to fractionate DENV-specific Abs in immune sera. Polystyrene
beads coated with virions of the homologous serotype were in-
cubated with immune sera at 37 °C to depleteDENV-bindingAbs.
Untreated and control-depleted serum samples bound to whole
virus from each of the four DENV serotypes by ELISA and effi-
ciently neutralized DENV (Fig. 1 A and B). Serum samples de-
pleted using beads coated with the homologous DENV displayed
greatly reduced binding and neutralization of DENV (Fig. 1A and
B), indicating that beads coated with the homologous serotype
successfully removedmostDENV-specificAbs from immune sera.
Depletion of Heterologous DENV-Specific Abs from Immune Sera.
Next, we assessed the contribution of DENV cross-reactive Abs in
immune sera to virus binding and neutralization. We used poly-
styrene beads coated with virus of a heterologous serotype (a
serotype that has not infected the DENV-immune subject) to
deplete cross-reactive Abs from primary immune sera (Fig. 1 and
Table 1). Depletion of primary DENV2-immune sera with
DENV3-coated beads led to the removal of all cross-reactive Abs,
with the remaining Abs binding to DENV2 in a type-specific
manner (Fig. 1C). Reciprocal depletion of primary DENV3-im-
mune sera with DENV2-coated beads removed all binding to
DENV2 and DENV4 but not to DENV3 and, to a lesser extent,
DENV1 (Fig. 1E). This residual DENV1-binding signal may be
attributable to Abs targeting subcomplex epitopes that are pref-
erentially shared between DENV1 and DENV3 (12, 13, 25).
Removal of cross-reactive Abs from primary immune sera did not
change the capacity of the sera to neutralize the virus responsible
for infection (Fig. 1 D and F, Fig. S1, and Table 1). These results
demonstrate that the DENV-specific human Ab response consists
of both cross-reactive and type-specific Abs. Although the sero-
type cross-reactive Abs were abundant, in the samples we ana-
lyzed, their contribution to neutralization was negligible. Thus,
type-specific Abs appear to be primarily responsible for neutral-
izing the homologous serotype.
Depletion of DENV Recombinant E Protein-Binding Abs from Immune
Sera. The organization of DENVE protein dimers on the surface of
the infectious virus has been modeled using crystal structures of
DENV recombinant E (rE) and cryo-EM reconstructions of the
virion (8, 10, 26, 27). Furthermore, neutralizing mouse mAbs have
been mapped extensively to the rE protein, and DENV subunit
vaccines using the rE protein are currently being developed (11–15,
28–30). We next assessed whether epitopes targeted by neutralizing
Abs in human immune sera were preserved on the rE protein.
DENV rE protein that was covalently coupled to agarose beads was
used to depleteAbs in immune sera. Serawere incubatedwith either
control beads or homologous rE-conjugated beads at 37 °C. The
structure of DENV rE on the beads was confirmed to be con-
formationally preserved, and rE dimers were confirmed to be intact
by successfully depleting mouse mAbs previously mapped to the
fusion loop (mAb 4G2), EDIII (mAb 9F16) (12), and E dimer in-
terface (mAbs DV2-10, DV2-46, and DV2-58) (11) (Fig. S2). We
also titrated the amount of rE protein on the beads required to
deplete rE-bindingAbs efficiently from immune sera (Fig. S3). Both
untreated and control-depleted immune sera bound to rE from all






















































































































































































Fig. 1. Binding and neutralization properties of primary DENV-immune sera
depleted of total or cross-reactive DENV-binding Abs. Total DENV-specific Abs
were removed from DENV3 primary immune serum (e.g., subject 011) using
polystyrene beads coated with purified DENV3 and tested for DENV binding
(A) and neutralization (B). The sera depleted with the homologous serotype
did not bind to any of the four DENVs and failed to neutralize DENV3. Similar
results were observed for four other primary immune sera (2 DENV2 and 2
DENV3 sera) depleted with the homologous serotype responsible for infection.
Primary DENV2 (C and D) and DENV3 (E and F) immune sera were depleted of
cross-reactive Abs using beads coated with virus of a heterologous serotype
and tested for DENV binding (C and E) and neutralization of the homologous
serotype (D and F). Immune sera depleted of cross-reactive Abs contained
type-specific Abs that bound to virus from the homologous serotype only.
Immune sera depleted of cross-reactive Abs were as potently neutralizing as
undepleted or control-depleted sera. Results presented here for cross-reactive
Ab depletions are representative of data obtained with four primary DENV2
and three primary DENV3 human immune sera (Table 1). *P < 0.001 by an
unpaired Student t test of mean binding values.
Table 1. Homologous DENV serotype neutralization titers of













Primary DENV2 001 2600 1650 1412
(2,040–2,700) (1,100–1,650) (1,060–1,600)
013 350 320 420
(260–470) (260–380) (370–550)
019 1202 1047 1000
(1,000–1,550) (930–1,580) (800–1,420)
031 1150 790 640
(1,000–1,310) (650–950) (540–740)
Primary DENV3 003 250 210 300
(230–350) (160–260) (250–360)
011 320 300 252
(265–390) (260–380) (211–300)
118 628 720 618
(510–770) (610–860) (500–750)
*Data are representative of experiments repeated at least three times for
each serum sample. The flow-based neutralization assay using U937 cells
stably expressing dendritic cell-specific intercellular adhesion molecule-3-
grabbing nonintegrin (DC-SIGN) was used to generate the reciprocal Neut50
values. The Neut50 values of undepleted, control-depleted, and cross-reac-
tive Ab-depleted sera were compared for each serum by one-way ANOVA
analysis. No statistical significance was found between control-depleted and
cross-reactive depleted groups for any of the tested sera.
†SEMs for reciprocal Neut50 values were calculated from the sigmoidal neu-
tralization curves using GraphPad Prism4 and are given in parentheses.
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four serotypes, but the binding was greatest for the homologous
serotype (Fig. 2 A and B). Depletion of primary immune sera using
homologous rE ablated binding to rE from each of the four sero-
types (Fig. 2 A and B). Successful depletion of rE-binding Abs was
also confirmed by Western blot, where rE and solubilized virions
were used as the antigen on the blot (Fig. 2C). By Western blot, we
could not detect binding to rE protein (which is missing 20% of the
native protein at the C terminus) or to full-length E protein from the
virus (Fig. 2C). These results established that beads coated with the
rE from the homologous serotype efficiently removed all Abs rec-
ognizing purified rE protein. We also measured the relative pro-
portion of virion-binding Abs in human immune sera that bound to
rE by comparing the binding of untreated, control-depleted, and rE-
depleted sera with the homologous virus by ELISA. Results dem-
onstrated an approximate 45 ± 7% reduction in DENV binding
following the removal of rE-binding Abs (Fig. S4 and Table S2),
indicating that approximately half of the DENV-specific Abs in
primary immune sera recognized the intact virus but not rE protein.
Next, we assessed the neutralizing activity of six immune sera
depleted of rE-binding Abs. Unexpectedly, four of the six immune
sera displayed no loss of neutralization potency after removal
of rE-binding Abs (Fig. 2 D and E and Table 2). One of the
three primary DENV2-immune sera and all three of the primary
DENV3-immune sera tested displayed no significant loss of neu-
tralization against the homotypic virus after removal of rE-specific
Abs. In contrast, two of the three primary DENV2-immune sera
displayed a statistically significant two- to threefold drop (P <
0.05) in the 50%neutralization (Neut50) titer when rE-specificAbs
were removed (Table 2). Sera from rhesus macaques (Macaca
mulatta) immunized with Venezuelan equine encephalitis virus
(VEEV) replicons expressing DENV3 E85 protein were used as
a positive control in these experiments. These animals should
develop neutralizing Abs that bind to rE protein; accordingly, rE-
coated beads removed >98% of the neutralizing Abs from these
vaccine sera (Fig. 2F). We conclude that although there was some
variation among human immune sera in the contribution of rE-
reactive Abs to homotypic DENV neutralization, a large fraction
of DENV neutralizing Abs in humans consists of neutralizing Abs
that bind to intact virions but not the rE protein.
Characterization of hmAbs That Strongly Neutralize DENV. As an
alternate approach to identify neutralizing viral epitopes tar-
geted by DENV-immune individuals, we generated a panel of
hmAbs that strongly neutralized DENV. These Abs were gen-
erated by transforming memory B cells from DENV-immune
subjects with EBV and generating hmAbs by electrofusion as
previously described (17). Because strongly neutralizing hmAbs
comprise a minor fraction of the total hmAbs isolated from
immune subjects (18–20), we used a two-step screen to isolate
strongly inhibitory Abs: We first identified Abs that bound to
DENV virions and then tested them for neutralizing activity. We
isolated three strongly neutralizing type-specific hmAbs (Neut50
value <0.2 μg/mL), designated 1F4, 2D22, and 5J7, that inhibited
infection of DENV1, DENV2, and DENV3, respectively. Two of
these hmAbs bound to the intact virus but not to rE (Table 3).
Generation of DENV Mutants That Escape Neutralization by hmAbs.
To map the epitopes engaged by neutralizing hmAbs, we sub-
jected the appropriate DENV serotype to Ab pressure and se-
lected for neutralization escape mutant viruses in vitro. DENV1,
DENV2, or DENV3 was passaged several times under varying
concentrations (0.2–10 μg/mL) of the neutralizing hmAb 1F4,
2D22, or 5J7, respectively. The original WT virus was passaged
in parallel in the absence of hmAb treatment. Structural genes of
the mutant and WT viruses were sequenced and compared to
identify the mutation(s) responsible for neutralization escape.
We successfully isolated two escape mutants against DENV1
type-specific mAb 1F4, with two independent single-nucleotide
mutations resulting in amino acid changes at position 274
(G→E) in the DI-DII hinge and 47 (K→E) in DI of the E protein
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Fig. 2. Binding and neutralization properties of primary
DENV-immune sera depleted of rE-binding Abs. DENV rE
from the homotypic strain was coupled covalently to
agarose beads and incubated with the relevant DENV-im-
mune sera to deplete DENV rE-specific Abs. (A and B)
Binding of immune sera to rE protein. Primary DENV2 (A)
and DENV3-immune (B) sera were depleted with DENV2
and DENV3 rE proteins, respectively, and binding to rE
protein from each of the four serotypes was measured by
ELISA. Depletion with the rE from the homologous sero-
type led to a loss of binding to rE protein from each of the
four serotypes. (C ) Successful removal of all rE-reactive Abs
from sera (e.g., primary DENV3-immune subject 003) also
was confirmed by Western blot analysis. Purified homo-
typic DENV (700 ng per well) and rE protein (500 ng per
well) were electrophoresed, transferred to nitrocellulose
membrane, and probed with undepleted, control-de-
pleted, or rE-depleted sera (at a 1:1,000 dilution). (D and E )
Neutralization of the homologous DENV by rE-depleted
sera was measured using a U937 + DC-SIGN flow cytom-
etry-based assay. Homologous DENV neutralization by
primary DENV2 (D; subject 031) and primary DENV3 (E;
subject 003) human immune sera depleted of rE-binding
Abs was tested. No reduction in neutralization potency
was observed following removal of rE-binding Abs from
either of these two serum samples. A total of six primary
immune sera were depleted of rE-binding Abs and tested
(Table 2). (F ) Nonhuman primates vaccinated with rE de-
velop neutralizing Abs that can be depleted with rE anti-
gen. Rhesus macaques (M. mulatta) were vaccinated and
boosted with an α-virus vector expressing DENV3 E ecto-
domain, and sera were collected 10 wk postvaccination.
Depletion of rE-binding Abs from sera of vaccinated ani-
mals (e.g., M630) removed greater than 98% (value estimated by comparing Neut50 values between control-depleted and rE-depleted sera) of the
neutralizing Abs. Data are representative of two vaccinated rhesus macaque controls.









(Fig. 3 A and D) that conferred loss of neutralization. K47 and
G274 are located 13.2 Å apart and likely comprise part of the
same 1F4 epitope. For the DENV2-specific neutralizing hmAb
2D22, we isolated one mutant with an EDIII mutation at residue
323 (R→G) that resulted in neutralization escape (Fig. 3 B and
E). Selection with the neutralizing DENV3-specific hmAb 5J7
resulted in an escape mutant with a lysine insertion in the E
DI-DII hinge region between the amino acid residues Q269 and
N270 (Fig. 3 C and F). All the mutated residues are surface-
exposed on the structure of the E protein dimer and within the
footprint of a complex epitope described for an hmAb (CR4354)
that strongly neutralized West Nile virus (WNV) (31, 32) (Fig. 3
G and H and Table 3).
Discussion
Although it has been known for several decades that humans
develop strongly neutralizing Abs following DENV infection, the
relevant Abs and epitopes on the virus have not been identified.
This is a major gap in knowledge, given the important roles
postulated for Abs in clearing DENV or enhancing infection and
disease. Here, the results from seven DENV-immune individuals
demonstrate that the DENV-specific human Ab response con-
sists of distinct populations of serotype cross-reactive and type-
specific Abs. The type-specific Abs were responsible for potent
neutralization of DENV. Although cross-reactive Abs were
abundant in human immune sera, their contribution to neutral-
ization was relatively negligible.
DENV serotype-specific neutralizing Abs generated in mice
bind to epitopes that are present on the soluble form of rE
protein (13–19). We report here that a substantial fraction of
DENV-reactive Abs in human immune sera, including type-
specific neutralizing Abs, bound to the intact virion but not to rE
protein. Some of these virion-specific Abs likely bind to prM or
M proteins, which also are displayed on the virion surface.
However, prM/M is unlikely to be the primary target of neu-
tralizing Abs, because several studies have shown that human
anti-prM Abs are highly cross-reactive and weakly neutralizing
(18–20). The rE protein used in this study was only 80% of the
full-length E protein and lacked the amphipathic helices, con-
served stem anchor, and transmembrane regions. Cryo-EM
reconstructions of mature virions demonstrate that the amphi-
pathic helices, stem anchor, and transmembrane segments are
not exposed on the surface, and therefore are unlikely to be the
targets of type-specific neutralizing Abs (8, 10, 26). Based on the
results of Ab depletion studies with human immune sera, we
suggest that the packing of E proteins on the virion surface
creates unique epitopes involving two or more E protein mole-
cules in adjacent symmetry groups, and that these quaternary
epitopes are targets of the human neutralizing Ab response.
Similar complex quaternary epitopes that are recognized by
potently neutralizing hmAbs have been described for several
other viruses, including WNV and HIV (31, 33, 34).
Our studies with hmAbs also confirmed that humans can
produce strongly neutralizing Abs that bind a quaternary epitope
expressed on intact virus particles but not on rE protein. The
strongly neutralizing hmAbs 1F4 and 5J7 selected for viruses that
escaped neutralization with mutations or insertions either on or
near the E DI-DII hinge region. Consistent with this, other
mAbs that strongly neutralize flaviviruses also have been repor-
ted to recognize the hinge region between EDI and EDII (31, 32,
35–37). Additionally, we identified a mutation at position 323 on
EDIII that resulted in neutralization escape from the anti-
DENV2 hmAb 2D22. This Ab likely also recognized a structur-
ally complex neutralizing epitope, because it bound to DENV2
particles but not to EDIII or rE from DENV2. Collectively, the
location of all four escape mutations identified for hmAbs 1F4,
2D22, and 5J7 (representing Abs that neutralize 3 different
serotypes in a type-specific manner) map to a region that over-
laps with an epitope recently described for the CR4354 hmAb
that strongly neutralized WNV in vitro and in vivo (31, 32), and
bound to virions but not to soluble E protein. Cryo-EM studies
revealed that the CR4354 footprint spanned the DI-DII hinge
Table 2. Homologous DENV serotype neutralization titers of










Primary DENV2 001† 660 850 260
(510–840) (690–950) (210–310)
019‡ 1,250 1,120 500
(1,010–1,500) (950–1,350) (400–600)
031 1,020 860 900
(790–1,300) (670–1,150) (690–1,190)
Primary DENV3 003 180 225 215
(155–250) (210–310) (150–220)
105 180 200 160
(140–235) (160–275) (130–185)
118 1,580 1,480 1,120
(1,180–2,020) (1,200–1,790) (900–1,400)
*Data are representative of experiments repeated at least three times for
each serum sample. SEMs for reciprocal Neut50 values were calculated from
the sigmoidal neutralization curves using GraphPad Prism4 and are given in
parentheses.
†There was a statistically significant difference between the undepleted/con-
trol-depleted and rE-depleted groups for samples by a one-way ANOVA,
followed by a Tukey multiple comparison test at P < 0.01.
‡There was a statistically significant difference between the undepleted and
rE-depleted groups when analyzed by a one-way ANOVA at P < 0.05.
Table 3. Binding and neutralization properties of strongly neutralizing hmAbs
mAbs









CR4354 epitope)§Virus rE EDIII prM† DENV1 DENV2 DENV3 DENV4
1F4 Type-specific (DENV1) − − − 0.11 >10 >10 >10 1 G274E DI-DII hinge 276 (contact site)
2 K47E DI 49 (contact site)
2D22{ Type-specific (DENV2) − − − >10 0.08 >10 >10 3 R323G DIII 326 (near contact site 328)
5J7{ Type-specific (DENV3) + − − >10 >10 0.10 >10 4 Q269_N271insK DI-DII hinge Before 274 (near contact
site 276)
*Binding of hmAbs (at 2 μg/mL) to DENV antigens was measured by ELISA.
†Binding to prM was determined by Western blot analysis.
‡Neut50 values were generated using the flow-based neutralization assay with U937 + DC-SIGN cells. Values in bold indicate the lowest Neut50 concentration
and the most neutralization sensitive serotype for each mAb.
§Comparison of the escape mutations generated against 1F4, 2D22, and 5J7 with the CR4354 epitope in WNV (31, 32).
{Binding and neutralization properties of 2D22 and 5J7 were taken from previous study (17).
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from one E protein dimer and DIII of the adjacent E dimer (31).
Abs that bind to this epitope were postulated to be strongly
neutralizing for two reasons: (i) each mature virion should have
120 of these epitopes available for interaction, of which 90%
could be simultaneously occupied by Ab (31), and (ii) Abs binding
to this EDI–EDII complex epitope could cross-link adjacent E
dimmers and inhibit trimer formation, which is a prerequisite for
viral fusion. Because all the escape mutants that we identified
localized within the footprint of CR4354, we propose that this
region is also a target of human neutralizing Abs against DENV.
Structure studies are in progress to define the relationships of
1F4, 2D22, and 5J7 with one another and with CR4354 further.
The EDI/II hinge region is not the only target of neutralizing
hmAbs. Strongly neutralizing hmAbs that bind to EDIII (including
A strand and lateral ridge epitopes recognized by mouse Abs)
have been isolated from memory B cells of DENV-immune sub-
jects (17–20). Further studies are needed to estimate the variety
and frequency of DENV-specific memory B cells encoding for
strongly neutralizing Abs. Such estimates are not possible from the
existing DENV hmAb literature because of the different methods
used to screen for DENV-specific memory B cells and the dif-
ferent criteria used to select B-cell clones and hmAbs for in-depth
study (17–20). Previous studies have demonstrated that human
immune sera depleted of EDIII Abs retained most of their neu-
tralizing activity (21). Similar to WNV, recombinant DENV with
mutations in EDIII lateral ridge and A-strand epitopes remained
sensitive to neutralization by human immune sera (22–24). In the
current study, we report that depletion of Abs that bind homol-
ogous rE also had more modest effects on neutralization potency,
whereas removal of Abs that bound intact homologous virus
13.2 A
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H
Fig. 3. Epitope mapping of escape mutants generated from type-specific neutralizing hmAbs. Neutralization profiles of respective WT and escape mutants
against 1F4 (A), 2D22 (B), and 5J7 (C). Neutralization escape by the mutant viruses was confirmed using U937 + DC-SIGN cells in a flow cytometry-based
neutralization assay for 1F4 and 2D22, and by focus reduction neutralization assay (FRNT) for 5J7. Display enlarged views indicate the positions of the original
amino acids of the escape mutations on EDIII and the EDI-EDII hinge region for 1F4 (D), 2D22 (E), and 5J7 (F). Images were generated with DENV1, DENV2, and
DENV3 E dimer structures, respectively. The DENV2 and DENV3 E dimer structures [Research Collaboratory for Structural Bioinformatics (RCSB) accession nos.
1OAN and 1UZG, respectively] (8, 9) were modeled using the UniProt protein database viewer and PyMOL (Schrödinger) to generate structures for DENV1 and
DENV3 (Thai 95) E dimers. (G) Alignment of E protein segments from DENV and WNV identified in the neutralizing hmAb-binding epitope of CR4354.
Mutations leading to escape from 1F4 (blue), 2D22 (green), or 5J7 (pink) are highlighted on relevant regions of the aligned DENV E protein sequences. A
portion of the CR4354 epitope that overlaps with the corresponding DENV escape mutations described here is highlighted in bold on the aligned WNV (New
York 2000) sequence. (H) Escape mutations were mapped onto the E polymeric structure generated for TBEV (RCSB accession no. 1K4R) (10). The positions of
escape mutations generated from 1F4, 2D22, and 5J7 are highlighted on the structure in blue (Gly274, K47), green (Arg323, His282, Asp362), and pink
(Gln271, Asn272) (i.e., residues surrounding the lysine insertion), respectively. The footprint of the anti-WNV CR4354 hmAb that spans E protein dimers is
circled with a white line. Note that all escape mutationsfor 1F4, 2D22, and 5J7 fall within the CR4354 footprint. *Neut50 values for each escape mutant
differed significantly from the respective WT virus (P < 0.0001).









resulted in a large decrease in neutralization titer. Collectively,
these observations suggest that Abs in human immune sera that
recognize the intact virus only account for the majority of the
inhibitory activity relative to those binding EDIII and rE protein.
Our findings reporting on a target of neutralizing human Abs
after natural infection are relevant to the development of DENV
vaccines and the evaluation of vaccines currently under devel-
opment. The leading dengue vaccine candidates currently being
tested in clinical trials consist of tetravalent formulations of live-
attenuated dengue or dengue/yellow fever chimeric viruses (38,
39). Studies are needed to determine if these live viral vaccines
also induce neutralizing Abs that bind to quaternary epitopes
expressed on the intact virion but not on soluble E protein.
Methods
Serum Samples. Human serum samples were collected from individuals who
had experienced a DENV infection during travel to an endemic region. Rhesus
macaque (Macaca mulatta) sera were taken from animals vaccinated with
a VEEV replicon particle (VRP-rE) expressing 80% of DENV3 E protein. More
information is provided in SI Methods.
Virus and rE Proteins. The DENV1 (West Pac 74), DENV2 (S-16803), DENV3 (CH-
53489 and Thailand 95), and DENV4 (TVP-360) strains were used in the present
study. All viruses used in the neutralization assays were grown in C6/36 Aedes
albopictus mosquito cells at 28 °C and titered on Vero-81 cells as previously
described (40). DENV was purified as previously described (21). The rE proteins
fromeachof the fourDENV serotypeswerepurchased fromHawaii Biotech, Inc.
Depletion of DENV-Specific Abs from Human Immune Sera. Purified DENVs
were adsorbed onto 4.0-μm Polybead polystyrene microspheres following
the manufacturer’s instructions (Polysciences, Inc.). Control beads were
adsorbed with BSA instead. Human immune sera were depleted of virus-
specific Abs by incubating sera with virus-adsorbed beads at 37 °C. Detailed
information is given in SI Methods.
Depletion of DENV rE-Specific Abs from Human and Monkey Immune Sera.
DENV rE proteins were covalently conjugated to cyanogen bromide (CNBr)-
activated beads following the manufacturer’s protocol (Sigma). Control
beads were conjugated with the blocking reagent instead of rE protein.
DENV rE-specific Abs were depleted by incubating human and rhesus ma-
caque immune sera with rE-conjugated beads at 37 °C. Detailed information
is given in SI Methods.
Detection of DENV or rE-Binding Abs by ELISA. ELISAs were conducted as
previously described (18). Sera were used at dilutions of 1:40 and 1:25 for the
depletion confirmation ELISAs in the virus and rE depletion experiments,
respectively. More information is provided in SI Methods.
Detection of rE-Binding Abs by Western Blot. Detailed information is provided
in SI Methods.
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